Q is this the drug Baloxavir Marboxil by shionogi effective against covid 19 be

https://www.shionogi.com/shionogi-to-present-new-data-at-2018-european-congress-of-clinical-microbiology-and-infectious-diseases/

https://www.shionogi.com/baloxavir-marboxil-phase-ii-and-iii-studies-for-the-treatment-of-influenza-published-in-the-new-england-journal-of-medicine/

https://www.shionogi.com/fda-accepts-xofluza-baloxavir-marboxil-supplemental-new-drug-application-for-the-treatment-of-influenza-in-individuals-at-high-risk-for-influenza-related-complications/

About Baloxavir Marboxil

Baloxavir marboxil, discovered and developed by Shionogi, has a novel mechanism of action that inhibits cap-dependent endonuclease, an essential enzyme for viral replication. The regimen for baloxavir marboxil is a single-oral dose to treat uncomplicated influenza, which is different from most currently available antiviral treatments. In non-clinical studies, baloxavir marboxil demonstrated an antiviral effect against a wide range of influenza viruses including oseltamivir-resistant strains and avian strains (H7N9, H5N1).12, 13, 14

Shionogi and the Roche Group which includes Genentech in the U.S. are in a license and collaboration agreement to further develop and commercialize baloxavir marboxil globally. Under the terms of this agreement, the Roche Group holds worldwide rights to baloxavir marboxil excluding Japan and Taiwan where the rights are retained exclusively by Shionogi. Roche will further investigate baloxavir marboxil in a global Phase III development program including pediatric and severely ill hospitalized populations with influenza. Shionogi will conduct a post-exposure Phase III prophylaxis study in Japan in the 2018/2019 flu season.